A Phase 2 interventional study of Telaprevir and Ribavirin in Hepatitis C, sponsored by Vertex Pharmaceuticals Incorporated. Terminated at 22 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-06-18.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing telaprevir in Hepatitis C — none open to participants now, none under way, none of them phase 3. telaprevir · Hepatitis C.
Among the 39 studies testing telaprevir in Hepatitis C, this one is the 14th largest by enrollment, is one of 12 that started in 2012, is one of 8 in phase 2, and was the 21st registered.
1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.
Browse Hepatitis C studies →None of the 39 studies testing telaprevir in Hepatitis C is open now. The open studies under Hepatitis C, anywhere →
telaprevir: first FDA approval 2011 (INCIVEK), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 9 · Phase 3 13 · Phase 4 5
First in 2005; this study’s year is marked. 12 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 61 is below the median of 73 across 1,224 interventional studies indexed under Hepatitis C.
Median enrollment 30 across the 39 interventional studies. Of the 37 that completed or were terminated, 20 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 39 have an industry lead sponsor. The 10 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
19 studies in Hepatitis C by Vertex Pharmaceuticals Incorporated: none open now, none under way, none of them phase 3. Of 19 finished, 9 (47%) have results posted.
Among the 19 studies in Hepatitis C by Vertex Pharmaceuticals Incorporated, this one is the 9th largest by enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2012, is one of 7 in phase 2, and was the 15th registered.
Vertex Pharmaceuticals Incorporated’s Hepatitis C studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 39 studies testing telaprevir in Hepatitis C, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Vertex Pharmaceuticals Incorporated’s 19 in Hepatitis C:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To assess efficacy of telaprevir, pegylated interferon alfa-2a (Peg-IFN-alfa-2a), and ribavirin (RBV) for hepatitis C virus (HCV) in a 48-week total treatment duration regimen following liver transplantation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who were receiving tacrolimus (TAC) based immunosuppressant regimen at baseline, received telaprevir (T) 1125 milligram (mg) tablet twice daily for 12 weeks in combination with pegylated interferon alfa 2a (P) (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (R) (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (\<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (\>=) 75 kg, for 48 weeks. Participants continued their immunosuppressant regimen, as per standard practice and investigator discretion.
Drug: Telaprevir · Drug: Ribavirin · Drug: Pegylated Interferon Alfa-2a · Drug: Immunosuppressant Regimen
Participants who were receiving cyclosporine (CsA) based immunosuppressant regimen at baseline, received telaprevir 1125 mg tablet twice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing \<75 kg and 1200 mg/day for subjects weighing \>=75 kg, for 48 weeks. Participants continued their immunosuppressant regimen, as per standard practice and investigator discretion.
Drug: Telaprevir · Drug: Ribavirin · Drug: Pegylated Interferon Alfa-2a · Drug: Immunosuppressant Regimen
Tablet
Also known as: VX-950
Tablet
Also known as: Copegus®, RBV
Subcutaneous Injection
Also known as: Pegasys®, Peg-IFN-alfa-2a
Cyclosporine (CsA) based immunosuppressant regimen or Tacrolimus (TAC) based immunosuppressant regimen, as per standard practice. Immunosuppressant regimen were not considered study drugs.
Percentage of Participants With Sustained Viral Response 12 Weeks After Last Planned Dose of Study Drug (SVR12)
SVR12 was defined as an undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (\<lower limit of quantification) at 12 weeks after last planned dose of study treatment. The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 international units per milliliter (IU/mL).
Time frame: 12 weeks after last planned dose of study drug (up to Week 60)
Percentage of Participants With Sustained Viral Response 24 Weeks After Last Planned Dose of Study Drug (SVR24)
SVR24 was defined as an undetectable HCV RNA Levels at 24 weeks after last planned dose of study treatment. The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL.
Time frame: 24 weeks after last planned dose of study drug (up to Week 72)
Percentage of Participants With Rapid Viral Response (RVR)
The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL and the lower limit of detection was 10 IU/mL. RVR was defined as undetectable HCV RNA 4 weeks after the start of study treatment.
Time frame: Week 4
Percentage of Participants With Extended Rapid Viral Response (eRVR)
The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL and the lower limit of detection was 10 IU/mL. eRVR was defined as undetectable HCV RNA at both 4 weeks and 12 weeks after the start of study treatment.
Time frame: Week 4 and Week 12
Percentage of Participants With On-Treatment Virologic Failure
On-treatment virologic failure was defined as subjects who met futility or who completed the assigned treatment duration and had detectable HCV RNA at planned end of treatment (up to 48 weeks). Data for this outcome was not planned to be reported by prior response.
Time frame: Baseline up to Week 48
Percentage of Participants With Viral Relapse
Time frame: 48 weeks
Pharmacokinetics of Telaprevir, Peg-IFN, RBV , and Selected Immunosuppressant Medications (Tacrolimus and Cyclosporine)
Time frame: 48 weeks
Percentage of Participants Requiring Dose Titration of Immunosuppressant Medications
Time frame: 48 weeks
Percentage of Participants With Biopsy Confirmed and Treated Rejection
Time frame: 48 weeks
Percentage of Participants With Histological Evidence of Stabilization or Improvement in Inflammation Grade or Fibrosis Stage
Time frame: 48 weeks
Number of Participants With Telaprevir Resistant HCV Variant at Non-Structural Viral Protein 3-4A (NS3-4A) Region
Time frame: 48 weeks
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Any adverse change from the participant's baseline (pre-treatment) condition, including any adverse experience, abnormal recording or clinical laboratory assessment value which occurs during the course of the study, whether it is considered related to the study drug or not. An adverse event includes any newly occurring event or previous condition that has increased in severity or frequency since the administration of study drug. SAE: medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. "Study drug" includes all investigational agents (including placebo, if applicable) administered during the course of the study.
Time frame: Baseline up to Week 52
Percentage of Participants With Sustained Viral Response 4 Weeks After Last Planned Dose of Study Drug (SVR4)
Time frame: 4 weeks after last planned dose of study drug (up to Week 52)
Study included Treatment-Naïve (no prior hepatitis C virus \[HCV\] therapy); Prior Relapser (prior treatment with pegylated interferon alfa/ribavirin \[Peg-IFN/RBV\] and experienced viral relapse); Prior Null/Partial Responder (prior treatment with Peg-IFN/RBV and had null/partial response); Uncategorized (could not tolerate treatment) participants.
| Milestone | T/PR + Immunosuppressant Regimen (Tacrolimus) | T/PR + Immunosuppressant Regimen (Cyclosporine) |
|---|---|---|
| Started | 51 | 10 |
| Completed | 18 | 7 |
| Not completed | 33 | 3 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Withdrawal by subject | 4 | 0 |
| Withdrew: Study terminated by sponsor | 28 | 3 |
SVR12 was defined as an undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (\<lower limit of quantification) at 12 weeks after last planned dose of study treatment. The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 international units per milliliter (IU/mL).
| percentage of participants | T/PR + Immunosuppressant Regimen (Tacrolimus) | T/PR + Immunosuppressant Regimen (Cyclosporine) |
|---|---|---|
| Naive (n= 16, 2) | 75.0 | 50.0 |
| Prior Relapser (n= 10, 2) | 60.0 | 100.0 |
| Prior Null Responder (n=16, 4) | 37.5 | 50.0 |
| Prior Partial Responder (n= 3, 1) | 66.7 | 100.0 |
| Uncategorized (n= 6, 1) | 50.0 | 100.0 |
| Total (n= 51, 10) | 56.9 | 70.0 |
SVR24 was defined as an undetectable HCV RNA Levels at 24 weeks after last planned dose of study treatment. The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL.
| percentage of participants | T/PR + Immunosuppressant Regimen (Tacrolimus) | T/PR + Immunosuppressant Regimen (Cyclosporine) |
|---|---|---|
| Naive (n= 5,1) | 60.0 | 0 |
| Prior Relapser (n= 4,1) | 25.0 | 0 |
| Prior Null Responder (n=10, 4) | 20.0 | 50.0 |
| Prior Partial Responder (n= 0, 1) | 0 | 100.0 |
| Uncategorized (n= 5, 0) | 20.0 | 0 |
| Total (n= 24, 7) | 29.2 | 42.9 |
The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL and the lower limit of detection was 10 IU/mL. RVR was defined as undetectable HCV RNA 4 weeks after the start of study treatment.
| percentage of participants | T/PR + Immunosuppressant Regimen (Tacrolimus) | T/PR + Immunosuppressant Regimen (Cyclosporine) |
|---|---|---|
| Naive (n= 16, 2) | 68.8 | 0 |
| Prior Relapser (n= 10, 2) | 50.0 | 50.0 |
| Prior Null Responder (n=16, 4) | 43.8 | 25.0 |
| Prior Partial Responder (n= 3, 1) | 66.7 | 100.0 |
| Uncategorized (n= 6, 1) | 33.3 | 0 |
| Total (n= 51, 10) | 52.9 | 30.0 |
The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL and the lower limit of detection was 10 IU/mL. eRVR was defined as undetectable HCV RNA at both 4 weeks and 12 weeks after the start of study treatment.
| percentage of participants | T/PR + Immunosuppressant Regimen (Tacrolimus) | T/PR + Immunosuppressant Regimen (Cyclosporine) |
|---|---|---|
| Naive (n= 16, 2) | 68.8 | 0 |
| Prior Relapser (n= 10, 2) | 50.0 | 50.0 |
| Prior Null Responder (n=16, 4) | 37.5 | 25.0 |
| Prior Partial Responder (n= 3, 1) | 66.7 | 100.0 |
| Uncategorized (n= 6, 1) | 33.3 | 0 |
| Total (n= 51, 10) | 51.0 | 30.0 |
On-treatment virologic failure was defined as subjects who met futility or who completed the assigned treatment duration and had detectable HCV RNA at planned end of treatment (up to 48 weeks). Data for this outcome was not planned to be reported by prior response.
| percentage of participants | T/PR + Immunosuppressant Regimen (Tacrolimus) | T/PR + Immunosuppressant Regimen (Cyclosporine) |
|---|---|---|
| Percentage of Participants With On-Treatment Virologic Failure | 0 | 0 |
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
Any adverse change from the participant's baseline (pre-treatment) condition, including any adverse experience, abnormal recording or clinical laboratory assessment value which occurs during the course of the study, whether it is considered related to the study drug or not. An adverse event includes any newly occurring event or previous condition that has increased in severity or frequency since the administration of study drug. SAE: medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. "Study drug" includes all investigational agents (including placebo, if applicable) administered during the course of the study.
| participants | T/PR + Immunosuppressant Regimen (Tacrolimus) | T/PR + Immunosuppressant Regimen (Cyclosporine) |
|---|---|---|
| AEs | 51 | 10 |
| SAEs | 11 | 3 |
No measurements were reported for this outcome.
Collected over Baseline up to Week 52. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| T/PR + Immunosuppressant Regimen (Tacrolimus) | — | 11/51 (21.6%) | 51/51 (100%) |
| T/PR + Immunosuppressant Regimen (Cyclosporine) | — | 3/10 (30%) | 10/10 (100%) |
| Event | T/PR + Immunosuppressant Regimen (Tacrolimus) | T/PR + Immunosuppressant Regimen (Cyclosporine) |
|---|---|---|
| Herpes zosterInfections and infestations | 0/51 | 1/10 |
| PneumoniaInfections and infestations | 0/51 | 1/10 |
| Coronary artery diseaseCardiac disorders | 0/51 | 1/10 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/51 | 1/10 |
| NauseaGastrointestinal disorders | 4/51 | 0/10 |
| VomitingGastrointestinal disorders | 4/51 | 0/10 |
| AnaemiaBlood and lymphatic system disorders | 2/51 | 0/10 |
| Impaired gastric emptyingGastrointestinal disorders | 1/51 | 0/10 |
| ProctalgiaGastrointestinal disorders | 1/51 | 0/10 |
| PainGeneral disorders | 1/51 | 0/10 |
| Event | T/PR + Immunosuppressant Regimen (Tacrolimus) | T/PR + Immunosuppressant Regimen (Cyclosporine) |
|---|---|---|
| FatigueGeneral disorders | 36/51 | 7/10 |
| RashSkin and subcutaneous tissue disorders | 18/51 | 7/10 |
| AnaemiaBlood and lymphatic system disorders | 28/51 | 7/10 |
| HeadacheNervous system disorders | 26/51 | 6/10 |
| NauseaGastrointestinal disorders | 29/51 | 4/10 |
| DiarrhoeaGastrointestinal disorders | 24/51 | 3/10 |
| PruritusSkin and subcutaneous tissue disorders | 21/51 | 2/10 |
| Anal pruritusGastrointestinal disorders | 7/51 | 4/10 |
| Anorectal discomfortGastrointestinal disorders | 14/51 | 3/10 |
| Influenza like illnessGeneral disorders | 6/51 | 3/10 |
Full analysis set included all participants who received at least 1 dose of study drug.
| Age, Continuous(Years) | T/PR + Immunosuppressant Regimen (Tacrolimus) | T/PR + Immunosuppressant Regimen (Cyclosporine) | Total |
|---|---|---|---|
| Mean | 56.8 ± 4.08 | 59.5 ± 2.95 | 57.3 ± 4.02 |
| Sex: Female, Male(Participants) | T/PR + Immunosuppressant Regimen (Tacrolimus) | T/PR + Immunosuppressant Regimen (Cyclosporine) | Total |
|---|---|---|---|
| Female | 12 | 0 | 12 |
| Male | 39 | 10 | 49 |
The record gives a start of Feb 2012, a primary completion of Apr 2014 and a completion of Apr 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2015, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Telaprevir · Ribavirin · Peginterferon alfa-2a
Vertex Pharmaceuticals Incorporated →